<DOC>
	<DOCNO>NCT00627432</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This randomized phase II trial study well give gemcitabine together oxaliplatin work compare gemcitabine alone treat patient locally advance metastatic bladder cancer .</brief_summary>
	<brief_title>Gemcitabine With Or Without Oxaliplatin Treating Patients With Locally Advanced Metastatic Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient advance urothelial cancer treat gemcitabine hydrochloride v without oxaliplatin . Secondary - Determine tolerance regimens patient . - Determine overall survival progression-free survival patient treat regimen . - Determine quality life patient treat regimen . - Determine duration response patient treat regimen . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV 120 minute day 1 , 8 , 15 . - Arm II : Patients receive gemcitabine IV 100 minute day 1 15 oxaliplatin IV 120 minute day 2 16 . Treatment arm repeat every 4 week 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm urothelial carcinoma , transitional cell carcinoma bladder upper urinary tract Locally advance disease ( T4b ) metastatic disease ( N2 , N3 , M1 ) Unable receive cisplatinbased chemotherapy due creatinine clearance 3060 mL/min performance status 2 At least 1 unidimensionally measurable lesion accord RECIST criterion No nonmeasurable lesion , include follow : Ascites Pleural pericardial effusion Bone metastases Lymphangitis No symptomatic cerebral metastasis unless stabilize PATIENT CHARACTERISTICS : See Disease Characteristics Performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Alkaline phosphatase ≤ 2 time normal ( unless bone metastasis present ) Transaminases ≤ 2 time normal ( 5 time normal hepatic metastasis present ) Bilirubin ≤ 1.5 time normal Not pregnant nursing Fertile patient must use effective contraception least 6 month completion treatment No prior malignancy within past 5 year except carcinoma situ cervix basal cell skin cancer No peripheral neuropathy ≥ grade 2 No uncontrolled infection No medical condition could interfere evaluate tolerability , include follow : Congestive heart failure Angina pectoris stabilize medication Myocardial infarction within past 12 month Serious thromboembolic disease No psychologic , social , geographic reason would make followup impossible PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy advanced disease More 4 week since prior radiotherapy target measurable lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>